MX2019001814A - Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart. - Google Patents

Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.

Info

Publication number
MX2019001814A
MX2019001814A MX2019001814A MX2019001814A MX2019001814A MX 2019001814 A MX2019001814 A MX 2019001814A MX 2019001814 A MX2019001814 A MX 2019001814A MX 2019001814 A MX2019001814 A MX 2019001814A MX 2019001814 A MX2019001814 A MX 2019001814A
Authority
MX
Mexico
Prior art keywords
treatment
hiv infection
haart
antibodies
sustained virologic
Prior art date
Application number
MX2019001814A
Other languages
English (en)
Inventor
Yi Wang Chang
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of MX2019001814A publication Critical patent/MX2019001814A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se dirige a composiciones y métodos para la prevención, tratamiento y/o curación funcional de la infección por VIH. Un aspecto de la presente descripción se relaciona con anticuerpos monoclonales dirigidos contra CD4, composiciones de los mismos, y métodos que emplean estas composiciones para la prevención, tratamiento y curación funcional de la infección por VIH.
MX2019001814A 2016-08-13 2017-08-13 Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart. MX2019001814A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662374752P 2016-08-13 2016-08-13
PCT/US2017/046668 WO2018035001A1 (en) 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Publications (1)

Publication Number Publication Date
MX2019001814A true MX2019001814A (es) 2019-07-08

Family

ID=61197201

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001814A MX2019001814A (es) 2016-08-13 2017-08-13 Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.

Country Status (14)

Country Link
US (1) US11292839B2 (es)
EP (1) EP3497133A4 (es)
JP (1) JP2019534891A (es)
KR (1) KR20190071677A (es)
CN (1) CN109996815A (es)
AU (1) AU2017312887A1 (es)
BR (1) BR112019002734A2 (es)
CA (1) CA3033728A1 (es)
MX (1) MX2019001814A (es)
RU (1) RU2019106804A (es)
SG (2) SG10202100268RA (es)
TW (1) TW201808998A (es)
WO (1) WO2018035001A1 (es)
ZA (1) ZA201901374B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11292839B2 (en) * 2016-08-13 2022-04-05 Ubi Us Holdings, Llc Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients
AU2020275049A1 (en) * 2019-05-16 2022-01-06 Nanjing Legend Biotech Co., Ltd. Engineered immune cells comprsing a recognition molecule
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381295A (en) 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
DE3828582A1 (de) 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
JPH0725794B2 (ja) 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US5871732A (en) 1990-11-27 1999-02-16 Biogen, Inc. Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
JPH06125783A (ja) 1991-12-28 1994-05-10 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ抗体およびその調製方法
DK0746613T3 (da) 1994-03-08 2006-09-25 Sloan Kettering Inst Cancer Rekombinante humaniserede antistoffer mod FB5
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5962319A (en) 1997-05-19 1999-10-05 Bml, Inc. Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
JP3231262B2 (ja) 1996-06-05 2001-11-19 株式会社ビー・エム・エル ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
JPH10155489A (ja) 1996-11-27 1998-06-16 Asahi Chem Ind Co Ltd 組換え抗体及びそれをコードする核酸
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
WO1999061629A1 (fr) 1998-05-25 1999-12-02 Asahi Kasei Kogyo Kabushiki Kaisha Dispositif pour la separation cellulaire et procede de separation
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
AR029337A1 (es) 1999-03-02 2003-06-25 Schering Corp Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv
DK1454137T3 (da) 2001-12-11 2008-06-16 Biotectid Gmbh Anvendelse af en mærket ligand med specificitet for det humane CD4-molekyle
JP2003327536A (ja) 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US20030211470A1 (en) 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1879617A1 (en) 2005-05-02 2008-01-23 Mymetics Corporation Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2
RU2393873C2 (ru) 2005-05-02 2010-07-10 Майметикс Корпорейшн Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2
WO2007025276A2 (en) 2005-08-25 2007-03-01 Government Of The United States Of America, As Represented By The Secretary Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies
WO2007094983A2 (en) 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
CA2884430A1 (en) 2012-09-07 2014-03-13 Baylor Research Institute Hiv vaccine compositions and methods
MX2015012709A (es) 2013-03-14 2016-05-31 Macrogenics Inc Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
CA2913231A1 (en) * 2013-05-24 2014-11-27 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
EP3194442A4 (en) * 2014-09-16 2018-05-23 UBI IP Holdings Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition
US11292839B2 (en) * 2016-08-13 2022-04-05 Ubi Us Holdings, Llc Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients

Also Published As

Publication number Publication date
ZA201901374B (en) 2022-04-28
AU2017312887A1 (en) 2019-03-07
RU2019106804A (ru) 2020-09-21
EP3497133A4 (en) 2020-03-25
US20190194326A1 (en) 2019-06-27
WO2018035001A1 (en) 2018-02-22
KR20190071677A (ko) 2019-06-24
CN109996815A (zh) 2019-07-09
RU2019106804A3 (es) 2021-03-29
CA3033728A1 (en) 2018-02-22
US11292839B2 (en) 2022-04-05
TW201808998A (zh) 2018-03-16
BR112019002734A2 (pt) 2019-05-14
JP2019534891A (ja) 2019-12-05
EP3497133A1 (en) 2019-06-19
SG10202100268RA (en) 2021-02-25
SG11201901203PA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
MX2022013524A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
EA201892294A1 (ru) Антитела и композиции против tim-3
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
EA201690905A1 (ru) Специфические антитела против cd38 для лечения злокачественных новообразований у человека
PH12015502261A1 (en) Macrocyclic deaza-purinones for the treatment of viral infections
EA201792182A1 (ru) Композиции и способы для лечения анемии
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
PH12015502564B1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
TW201611845A (en) Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
MX2019014291A (es) Metodo de tratamiento.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2020006368A (es) Uso de tratamiento combinado de anticuerpo pd-1 y apatinib para tratar cancer de mama triple negativo.
EA202092573A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA202091738A1 (ru) Способы лечения рака антителами-антагонистами к pd-1